Shattuck Labs

SHATTUCK LABS INC

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Shattuck Labs Inc

Health Care

Press Releases

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Earnings

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

News

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Financing

Management

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

IRON

STTK

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Biomea Fusion

Climb Bio

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coya Therapeutics

EXoZymes

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Opus Genetics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MDxHealth

Macrogenics

Metagenomi

Ovid Therapeutics

Quince Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Surrozen

TScan Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Shattuck Labs

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO